Clinical Registry on Sudden Death Primary Prevention at Latin America

Myocardial Infarction Clinical Trial

— ESCAPE-ICD  

Official title:

Clinical Registry on Sudden Death Primary Prevention at Latin America (rEgiStro Clinico en America Latina de Prevencion Primaria en muErte Subita)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01422174
• Other study ID #: TA098
• Status: Withdrawn
• Phase: N/A
• First received: August 18, 2011
• Last updated: March 2, 2015
• Start date: March 2012
• Est. completion date: January 2015

Study information

• Verified date: March 2015
• Source: Biotronik SE & Co. KG
• Contact: n/a
• Is FDA regulated: No
• Health authority: Argentina: Institute for Clinical Effectiveness and Health PolicyColombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y AlimentosChile: Comisión Nacional de Investigación Científica y TecnológicaBrazil: National Committee of Ethics in Research
• Study type: Observational

Clinical Trial Summary

INTRODUCTION: Sudden cardiac death is one of the most important reasons of death at industrialized countries. Despite its importance, nowadays Clinical Guidelines are not as extended as expected, with respect to indications for primary prevention defibrillator implantation, following MADIT II and MUSTT criteria, especially at Latin American countries.

OBJECTIVES: This Project is designed with the purpose of providing tools to help spreading primary prevention by the means of clinical evidence on real risk of death in this group of patients.

REGISTRY DESIGN:

• retrospective (at stage 1); prospective (at stage 2)

• multi-center (minimum 25-30 centres)

• international (Argentina, Brazil, Colombia, Chile, Mexico and Venezuela)

• non randomized.

• Sample size: at screening about 12.500 patients and 962 patients at treatment stage

REGISTRY DEVICES: CE marked (Conformité Européenne) single-chamber, dual-chamber or CRT (Cardiac Resynchronization Therapy) implantable cardiac defibrillator (ICD).

Description:

REGISTRY STAGES 2 stages will be performed:

• Stage 1 (Screening): 12500 patients with MI and LVEF<40% will be evaluated, to know ICD implantation prevalence in such patients at Latin American countries

• Stage 2 (Treatment): after patient screening and as per clinical decision, 962 patients will be entered in group 1 and 2 (481 each, 1:1)

STEERING COMMITTEE

• Dr. Sergio Dubner. Clinica y Maternidad Suizo Argentina and De Los Arcos Sanatorio. Buenos Aires - Argentina

• Dr. William Uribe. CES CARDIOLOGIA. Medellin - Colombia

CLINICAL ASSESSMENT

• Dr Francisco Javier Alzueta Rodriguez. Hospital Clinico Universitario Virgen de la Victoria. Malaga - Spain

REGISTRY DURATION

• Patient enrollment period initiation: September 2011

• End of patient enrollment: September 2013

• End of FUs: September 2018

• Registry closure and data analyses: 4Q 2018.

REGULATORY CONSIDERATIONS As this is an observational registry, no submission to National Authorities is required.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients that had Acute Myocardial Infarction (>40 days post-AMI) documented with the presence of Q-wave or cardiac-specific enzymatic markers of myocardial necrosis (CK-MB/troponin), occurred within 3 years previous to enrollment / after June 2008.

• Left Ventricular Ejection Fraction (LVEF) =40% post-revascularization (if no revascularization, measurement performed <3 months previous to patient enrollment, >40 days post-AMI and >3 months post-revascularization -if applicable-).

Exclusion Criteria:

• Patient with an implanted ICD

• <18 years old

• Pregnant or breast feeding women

• Patients that are already participating in other Investigational Study or Registry

• Non signed patient informed consent or refusal from patient's reference physician to patient participation

• Patient inability to comply with protocol (assist to scheduled follow-ups), due to:

residence displacement out of center's activity area; unstable geographical situation or at very long distance from the center; unstable medical and/or psychological condition

• Cardiac transplanted (or in transplant waiting list)

• Severe Heart Failure (or other co-morbidity: cancer, renal failure, etc.)

• Life expectancy lower than 1 year

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Death
• Death, Sudden
• Infarction
• Myocardial Infarction
• Sudden Death

Intervention

Procedure:
• Implantable Cardio Defibrillator (ICD),
Standard ICD implantation (as per clinical decision)

Locations

Country	Name	City	State
Argentina	Centro Privado de Cardiologia	Tucuman

Sponsors (1)

Lead Sponsor	Collaborator
Biotronik SE & Co. KG

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of patients with MADIT, MADIT II and MUST at Latin American countries	Primary Outcome at Stage 1: Determine prevalence of patients with myocardial infarction and high risk of sudden death at Latin America, that fulfill inclusion criteria; Primary Outcome at Stage 2: Compare MACE development in patients that receive ICD implantation vs patients that receive other type of treatment (non ICD)	Patients that suffered from MI in the last 3 years and during the enrollment period	No
Secondary	Study incidence of Arrhythmic mortality and serious arrhythmic events, evaluated through remote monitoring		5 years (until end 2018)	No